These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23700092)

  • 1. Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein-Barr virus or adenovirus after allogeneic stem cell transplantation.
    Feucht J; Joachim L; Lang P; Feuchtinger T
    Klin Padiatr; 2013 May; 225(3):164-9. PubMed ID: 23700092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
    Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
    J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant.
    Comoli P; Basso S; Labirio M; Baldanti F; Maccario R; Locatelli F
    Blood Cells Mol Dis; 2008; 40(1):68-70. PubMed ID: 17904879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.
    Gerdemann U; Katari UL; Papadopoulou A; Keirnan JM; Craddock JA; Liu H; Martinez CA; Kennedy-Nasser A; Leung KS; Gottschalk SM; Krance RA; Brenner MK; Rooney CM; Heslop HE; Leen AM
    Mol Ther; 2013 Nov; 21(11):2113-21. PubMed ID: 23783429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
    Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
    Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
    Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients.
    Pagliara D; Savoldo B
    Curr Opin Infect Dis; 2012 Aug; 25(4):431-7. PubMed ID: 22614521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for transplantation-associated viral infections.
    Roddie C; Peggs KS
    J Clin Invest; 2017 Jun; 127(7):2513-2522. PubMed ID: 28628043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.
    Freimüller C; Stemberger J; Artwohl M; Germeroth L; Witt V; Fischer G; Tischer S; Eiz-Vesper B; Knippertz I; Dörrie J; Schaft N; Lion T; Fritsch G; Geyeregger R
    Cytotherapy; 2015 Jul; 17(7):989-1007. PubMed ID: 25866178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus- and cytomegalovirus-specific adoptive T-cell therapy in the context of hematologic cell transplant or HIV infection - A single-center experience.
    Obermaier B; Braun C; Hensen L; Ahmad O; Faul C; Lang P; Bethge W; Lengerke C; Vogel W
    Transpl Infect Dis; 2024 Aug; 26(4):e14296. PubMed ID: 38830809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.
    Zandvliet ML; van Liempt E; Jedema I; Kruithof S; Kester MG; Guchelaar HJ; Falkenburg JH; Meij P
    J Immunother; 2011 Apr; 34(3):307-19. PubMed ID: 21389867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: an update.
    Feuchtinger T; Richard C; Pfeiffer M; Neuhäuser F; Lücke J; Handgretinger R; Greil J; Bader P; Klingebiel T; Schlegel PG; Jahn G; Niethammer D; Lang P
    Klin Padiatr; 2005; 217(6):339-44. PubMed ID: 16307420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
    Peggs KS; Mackinnon S
    Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of stem cell graft on early viral infections and immune reconstitution after allogeneic transplantation in adults.
    Illiaquer M; Imbert-Marcille BM; Guillaume T; Planche L; Rimbert M; Bressollette-Bodin C; Le Bourgeois A; Peterlin P; Garnier A; Le Houerou C; Moreau P; Mohty M; Chevallier P
    J Clin Virol; 2017 Aug; 93():30-36. PubMed ID: 28601677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells.
    Mackinnon S; Thomson K; Verfuerth S; Peggs K; Lowdell M
    Blood Cells Mol Dis; 2008; 40(1):63-7. PubMed ID: 17869548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High level of perforin expression in T cells: An early prognostic marker of the severity of herpesvirus reactivation after allogeneic stem cell transplantation in adults.
    Pietersma FL; van Dorp S; Jacobi R; Ran L; Nanlohy NM; Schuurman R; Minnema MC; Meijer E; van Baarle D
    Clin Infect Dis; 2010 Mar; 50(5):717-25. PubMed ID: 20121571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group.
    Koehl U; Dirkwinkel E; Koenig M; Erben S; Soerensen J; Bader P; Doerr HW; Preiser W; Weissinger E; Klingebiel T; Martin H; Lehrnbecher T
    Klin Padiatr; 2008; 220(6):348-52. PubMed ID: 18949669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive transfer of cytomegalovirus/Epstein-Barr virus-specific immune effector cells for therapeutic and preventive/preemptive treatment of pediatric allogeneic cell transplant recipients.
    Dong L; Gao ZY; Chang LJ; Liang Y; Tan XY; Liu JH; Yu XJ; Yang FH; Xie Y; Lu DP
    J Pediatr Hematol Oncol; 2010 Jan; 32(1):e31-7. PubMed ID: 20051775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation.
    Feuchtinger T; Matthes-Martin S; Richard C; Lion T; Fuhrer M; Hamprecht K; Handgretinger R; Peters C; Schuster FR; Beck R; Schumm M; Lotfi R; Jahn G; Lang P
    Br J Haematol; 2006 Jul; 134(1):64-76. PubMed ID: 16803570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.